Holen Sie sich die Stockscreener-App
83.65
0.84%
0.5251
Schlusskurs vom Vortag:
$83.12
Offen:
$83.18
24-Stunden-Volumen:
93,617
Relative Volume:
0.07
Marktkapitalisierung:
$8.96B
Einnahmen:
$769.10M
Nettoeinkommen (Verlust:
$46.67M
KGV:
238.99
EPS:
0.35
Netto-Cashflow:
$119.79M
1W Leistung:
+8.17%
1M Leistung:
+48.70%
6M Leistung:
+3.33%
1J Leistung:
+18.23%
1-Tages-Spanne:
$82.13
$84.00
1-Wochen-Bereich:
$76.52
$84.79
52-Wochen-Spanne:
$28.66
$91.00
Corcept Therapeutics Inc Stock (CORT) Company Profile
Firmenname
Corcept Therapeutics Inc
Sektor
Branche
Telefon
650.688.8803
Adresse
101 REDWOOD SHORES PARKWAY, REDWOOD CITY
Compare CORT vs VRTX, REGN, ARGX, ALNY, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
CORT
Corcept Therapeutics Inc
|
83.50 | 8.92B | 769.10M | 46.67M | 119.79M | 0.35 |
VRTX
Vertex Pharmaceuticals Inc
|
453.01 | 114.33B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
614.57 | 64.47B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
877.53 | 54.99B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
279.78 | 38.42B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
156.79 | 34.03B | 742.00K | -1.37B | -1.07B | -7.0731 |
Corcept Therapeutics Inc Stock (CORT) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-03-26 | Hochstufung | Wolfe Research | Underperform → Peer Perform |
| 2025-12-31 | Herabstufung | Wolfe Research | Peer Perform → Underperform |
| 2025-12-16 | Eingeleitet | UBS | Neutral |
| 2025-11-18 | Eingeleitet | Wolfe Research | Peer Perform |
| 2023-11-06 | Hochstufung | Truist | Hold → Buy |
| 2023-04-11 | Eingeleitet | SVB Securities | Market Perform |
| 2023-04-04 | Eingeleitet | Piper Sandler | Overweight |
| 2023-02-15 | Herabstufung | Jefferies | Buy → Hold |
| 2022-08-01 | Herabstufung | Truist | Buy → Hold |
| 2022-07-27 | Hochstufung | Jefferies | Hold → Buy |
| 2022-06-27 | Fortgesetzt | Canaccord Genuity | Buy |
| 2022-02-02 | Eingeleitet | Canaccord Genuity | Buy |
| 2022-01-28 | Eingeleitet | Truist | Buy |
| 2020-08-05 | Herabstufung | Jefferies | Buy → Hold |
| 2019-09-24 | Eingeleitet | Jefferies | Buy |
| 2019-09-06 | Eingeleitet | H.C. Wainwright | Buy |
| 2019-02-04 | Herabstufung | B. Riley FBR | Buy → Neutral |
| 2018-08-10 | Bestätigt | Stifel | Hold |
| 2018-05-31 | Herabstufung | Stifel | Buy → Hold |
| 2018-03-09 | Eingeleitet | B. Riley FBR, Inc. | Buy |
| 2017-08-31 | Eingeleitet | Stifel | Buy |
| 2017-02-02 | Eingeleitet | Ladenburg Thalmann | Buy |
| 2015-04-21 | Eingeleitet | FBR Capital | Outperform |
| 2014-01-13 | Herabstufung | Stifel | Buy → Hold |
| 2013-08-09 | Herabstufung | Janney | Buy → Neutral |
| 2013-08-09 | Herabstufung | Ladenburg Thalmann | Buy → Neutral |
| 2012-02-21 | Bestätigt | JMP Securities | Mkt Outperform |
| 2010-01-06 | Hochstufung | Ladenburg Thalmann | Neutral → Buy |
| 2008-07-17 | Eingeleitet | Rodman & Renshaw | Mkt Outperform |
| 2007-06-21 | Hochstufung | Punk, Ziegel & Co | Mkt Perform → Accumulate |
Alle ansehen
Corcept Therapeutics Inc Aktie (CORT) Neueste Nachrichten
CORT Stock Skyrockets 35% After Early FDA Nod For Ovarian Cancer Drug - Stocktwits
symbol__ Stock Quote Price and Forecast - CNN
Korlym improves results for diabetes patients taking GLP-1 drugs - Cushing's Disease News
Catalyst and Momentum Trials Data Fuels Optimism for Corcept Therapeutics (CORT) - Yahoo Finance
CORT Stock Slips After-Hours On Weak Q4 Print: Retail Is Watching April FDA Meeting For Relacorilant As Next Catalyst - Stocktwits
Norges Bank Purchases New Holdings in Corcept Therapeutics Incorporated $CORT - MarketBeat
Clearbridge Investments LLC Has $17.66 Million Position in Corcept Therapeutics Incorporated $CORT - MarketBeat
CORT to resubmit NDA for relacorilant in Cushing's syndrome, stock up - MSN
7 Health Care Stocks With Whale Alerts In Today's Session - Benzinga
CORT Stock Rises 42% in a Month: Here's What You Should Know - The Globe and Mail
Corcept Therapeutics (CORT) Reveals Promising Trial Data on Diab - GuruFocus
Corcept Therapeutics (CORT) Reveals Promising Trial Data on Diabetes Treatment - GuruFocus
Geode Capital Management LLC Acquires 734,646 Shares of Corcept Therapeutics Incorporated $CORT - MarketBeat
Corcept Presents New Data at ADA: Improved Outcomes in Patients Receiving a GLP-1 with Difficult-to-Control Type 2 Diabetes and Hypercortisolism Treated with Korlym® - Lelezard
Legal & General Group Plc Decreases Holdings in Corcept Therapeutics Incorporated $CORT - MarketBeat
Corcept Therapeutics Stock On Fire: Up 36% With 12-Day Winning Streak - Trefis
CORT Stock Chart | CORCEPT THERAPEUTICS INC (NASDAQ:CORT) - ChartMill
Corcept Therapeutics Stock 12-Day Winning Spree: Stock Climbs 36% - Trefis
Corcept Therapeutics chief development officer sells $1.41m stock By Investing.com - Investing.com Australia
Corcept Therapeutics chief development officer sells $1.41m stock - Investing.com UK
Adrenocortical Carcinoma Market Forecast Signals Robust - openPR.com
Adrenocortical Carcinoma Market Forecast Signals Robust Industry Growth Through 2036 – DelveInsight | Orphagen Pharma, Corcept Therapeutics, Cytovation, Merck, Enterome, Bristol-Myers Squibb, UNICANCE - Barchart
Corcept (NASDAQ: CORT) CDO sells 20K shares under 10b5-1 plan - Stock Titan
State Street SPDR S&P Pharmaceuticals vs First Trust NYSE Arca Biotech: Which Is the Better ETF For Your Portfolio? - The Motley Fool
Corcept Faces Amended Qui Tam Complaint After DOJ Exit - The Globe and Mail
Corcept Therapeutics president Sean Maduck sells $1.76m in stock - Investing.com UK
11-Day Rally Sends Corcept Therapeutics Stock Up 32% - Trefis
Corcept Therapeutics Stock Surges 32%, With A 11-Day Winning Spree - Trefis
Corcept Therapeutics president Sean Maduck sells $1.76m in stock By Investing.com - Investing.com Australia
Corcept Therapeutics CFO sells $2.8m in company stock - Investing.com
Corcept Therapeutics CFO sells $2.8m in company stock By Investing.com - Investing.com Australia
Corcept (NASDAQ: CORT) officer reports stock grants and tax share withholding - Stock Titan
Corcept (NASDAQ: CORT) CDO acquires 1,754 shares via grant and purchase plan - Stock Titan
Corcept (CORT) officer sells 25K shares after option exercise under 10b5-1 plan - Stock Titan
Corcept Therapeutics (CORT) CFO executes 40,000-share option exercise-and-sale under 10b5-1 plan - Stock Titan
Corcept (NASDAQ: CORT) CBO reports equity awards and tax-share withholding - Stock Titan
[8-K] CORCEPT THERAPEUTICS INC Reports Material Event - Stock Titan
DOJ Declines Intervention in Qui Tam Suit Against Corcept; Relator Amends Complaint - TradingView
Corcept Therapeutics Stock 10-Day Winning Spree: Stock Climbs 29% - Trefis
Corcept Therapeutics Stock On Fire: Up 29% With 10-Day Winning Streak - Trefis
Corcept (NASDAQ: CORT) CEO trust sale and 600,000-share gifts disclosed - Stock Titan
Corcept (CORT) insider resale notice: 20,000 shares via option exercise (06/02/2026) - Stock Titan
Corcept Therapeutics Stock On Fire: Up 21% With 9-Day Winning Streak - Trefis
H.C. Wainwright Keeps Their Buy Rating on Corcept Therapeutics (CORT) - The Globe and Mail
H.C. Wainwright reiterates Corcept stock rating on ASCO data By Investing.com - Investing.com Canada
Corcept Therapeutics Stock Surges 28%, With A 9-Day Winning Spree - Trefis
CORT (NASDAQ: CORT) Rule 144 notice: 160,000 shares via Stifel - Stock Titan
Joseph Belanoff sells 66,198 CORT shares; Form 144 filed (CORT) - Stock Titan
Corcept Therapeutics Insider Sold Shares Worth $325,000, According to a Recent SEC Filing - Moomoo
Piper Sandler Maintains Corcept Therapeutics(CORT.US) With Buy Rating, Maintains Target Price $88 - Moomoo
Corcept Therapeutics Insider Sold Shares Worth $4,918,944, According to a Recent SEC Filing - Moomoo
Finanzdaten der Corcept Therapeutics Inc-Aktie (CORT)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.61%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):